Humana Inc. (NYSE:HUM) Plans $0.89 Quarterly Dividend

Humana Inc. (NYSE:HUM) announced a quarterly dividend on Thursday, October 24th, RTT News reports. Stockholders of record on Tuesday, December 31st will be paid a dividend of 0.885 per share by the insurance provider on Friday, January 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.37%.

Humana has raised its dividend payment by an average of 12.3% annually over the last three years. Humana has a dividend payout ratio of 17.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect Humana to earn $19.70 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 18.0%.

Humana Trading Down 0.0 %

NYSE HUM traded down $0.07 during trading on Thursday, reaching $258.58. 1,675,783 shares of the stock traded hands, compared to its average volume of 1,852,383. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $527.18. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a market cap of $31.16 billion, a price-to-earnings ratio of 16.10, a price-to-earnings-growth ratio of 1.91 and a beta of 0.50. The stock’s 50-day moving average price is $310.28 and its 200 day moving average price is $337.43.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.94 EPS. Analysts predict that Humana will post 16.06 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on HUM. UBS Group decreased their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Stephens reaffirmed an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a research report on Wednesday, October 9th. Deutsche Bank Aktiengesellschaft lowered their target price on Humana from $349.00 to $250.00 and set a “hold” rating for the company in a report on Thursday, October 3rd. Finally, TD Cowen lowered Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $402.00 to $261.00 in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.